BMS bags a patent for its HCV trial drug

BRISTOL-MYERS SQUIBB COMPANY has filed an Indian patent application IN 9336/DELNP/2008 claiming cyclopropyl fused indolobenzazepine compounds which covers Beclabuvir (BMS-791325) an antiviral drug for the treatment of hepatitis C virus (HCV) infection currently in clinical trials. Beclabuvir acts as a NS5B inhibitor.

india drug

IN ‘9336 was entered in India through PCT/US2007/068209 (published as WO 2007/136982), a hearing was offered to applicant on January 22, 2016 regarding the objections raised by the examiner.

Applicant has made his observations / arguments and filed amended set of claims, the examiner was satisfied with respect to all the objections raised previously and allowed the application for grant containing 16 claims, as of now there is no patent number assigned for this application. The decision can be find here.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s